Trending Topics


Check out the latest cancer-related news and also see who is readily available to offer reliable information, expert commentary, and reaction to today’s headlines.
Contact a media coordinator

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).
Wednesday, October 2, 2019
A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside the chest. The updated PACIFIC trial data will be presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO), by Andreas Rimner, MD, radiation oncologist, Memorial Sloan Kettering Cancer Center.
Monday, September 16, 2019
Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer demonstrates selpercatinib’s marked antitumor activity in RET fusion-position non-small cell lung cancer (NSCLC) patients. These findings, presented by Alexander Drilon, MD, principal investigator and Research Director of Early Drug Development at Memorial Sloan Kettering Cancer Center, will form the basis of an US Food and Drug Administration new drug application submission.
Monday, September 9, 2019
See all trending topics

Press Releases


Memorial Sloan Kettering Cancer Center (MSK) today announced that Claus Torp Jensen, PhD, has joined the institution as its first Chief Digital Officer and Head of Technology.
Monday, October 14, 2019
After an extensive nationwide search, Memorial Sloan Kettering Cancer Center (MSK) announced today that Lisa M. DeAngelis has been named Physician-in-Chief and Chief Medical Officer. A leading expert in brain cancer, Dr. DeAngelis previously served as Chair of the Department of Neurology and was co-founder of MSK’s Brain Tumor Center during her 30-plus-year tenure at the institution.
Tuesday, September 10, 2019
Researchers from Memorial Sloan Kettering Cancer Center (MSK) shared new data from a survey of members of the Society of Gynecologic Oncology (SGO) showing that sexual harassment and observed gender discrimination continue to be significant issues in the medical community. The results of the study found that more than 60 percent of gynecologic oncologists had experienced sexual harassment, while only 10 percent of survey respondents reported the incident. The findings were presented as part of the press program for this year’s annual meeting of the American Society of Clinical Oncology (ASCO).
Monday, June 3, 2019
See all press releases

On Our Blog


Learn about the 19 students who completed the 2019 Summer Undergraduate Research Program (SURP) at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK).
Monday, October 14, 2019
Discover some of the latest innovations in chemotherapy for breast cancer.
Thursday, October 10, 2019
Find out how to handle feelings of self-blame and shame that may accompany a cancer diagnosis.
Wednesday, October 9, 2019
See all blog posts

Media Coverage


The research could lead to new treatments for potentially deadly conditions including cancer, heart attack and stroke. MSK’s Joan Massagué is quoted.
Tuesday, October 8, 2019
MSK’s Larry Norton discusses the latest research and advancements in the treatment of breast cancer.   
Friday, October 4, 2019
Though breast cancer strikes men much less often than women, a new study in the Journal of the American Medical Association [JAMA] reveals that three to five years after a breast cancer diagnosis, men are less likely to be alive. MSK’s Monica Morrow is featured.
Wednesday, October 2, 2019
See all media coverage

If you wish to contact MSK about a marketing or advertising related opportunity, or are looking for additional information about our ad campaign, please email us at

Jeanne D'Agostino
Director, Media and Public Relations
Emily O'Donnell
Media Relations Manager, Surgery
Courtney Nowak
Media Relations Manager, Regional Care Network
Caitlin Hool
Senior Manager, Media Relations and Partnerships
Nicole H. McNamara
Senior Media Strategist
Rebecca Williams
Media Strategist
For press inquiries, our Media Staff are available by calling 646-227-3573 or by dialing the numbers above. Our office hours are Monday - Friday, 9:00 am to 5:00 pm.
After hours, please contact the hospital’s page operator at 212-639-7900 and ask for the Public Affairs representative on-call.

Live and Remote Broadcast Capabilities

Our experts can offer live broadcast interviews using the on-site studio system. To book an expert interview using our on-site broadcast studio contact our Media Staff.

Contact our Media Staff